1,720,988 research outputs found
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.
No full text
Impact of natalizumab treatment on cognitive performance, fatigue and health-related quality of life in relapsing multiple sclerosis
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.
No full textThe impact of neutralizing antibodies (NAbs)
on interferon b (IFNb) efficacy in MS patients is still an
object of controversy. To evaluate the clinical response to
IFNb during NAb-positive (NAb?) and NAb-negative
(NAb-) statuses on a large population of relapsing
remitting (RR) MS patients were followed up to 5 years.
Sera from 567 RR MS patients treated with IFNb for
2–5 years were collected every 6–12 months and evaluated
for NAb presence by a cytopathic effect assay. The relapse
rate and expanded disability status scale (EDSS) score
were assessed at baseline and every 6 months for each
patient. A NAb? status was defined after two consecutive
positive titers of NAbs[/= 20 neutralizing units (NU)/mL.
Multivariate models were used to analyze the relapse rate,
the time to first relapse, the time to confirmed EDSS score
4 during NAb? and NAb- statuses. A propensity score
(PS) matching analysis was performed to assess the
robustness of the multivariate models. Fourteen percent of
patients became NAb? during the follow-up. A significant
increase of the relapse rate (IRR = 1.38; p = 0.0247) and
decrease of the time to 1st relapse (IRR = 1.51;
p = 0.0111) were found during NAb? periods. The PS
matching analysis, in a selected cohort of patients, demonstrated
a negative trend of NAbs on the time to reach the
milestone EDSS 4 (IRR = 2.94; p = 0.0879). This longterm
post-marketing observational study further confirms
that the occurrence of NAbs significantly affects the risk of
disease worsening in IFNb- treated RRM
Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender
No full textNatalizumab treatment affects cognitive performances, fatigue and health related quality of life in Relapsing Multiple Sclerosis
No full textChanges of Cognitive Performances, Fatigue and Health Related Quality of Life in Natalizumab-Treated Relapsing Multiple Sclerosis Patients
No full textPostmarketing evidence of disease-modifying drugs in multiple sclerosis
No full textThere is growing interest in the use of observational data to estimate treatment effects in chronic diseases such as multiple sclerosis (MS). The main results derived from postmarketing evaluations, in the last 2 years, of short-and long-term disease modifying drugs (DMDs) effectiveness will be reported in this Review. Moreover, some of the methodological improvements that may be useful to enhance the quality of observational studies will also be discussed
- …
